Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Sage Therapeutics will report the first pivotal data with its oral postpartum depression candidate, while Biohaven Pharma transfers its hopes to a faster-acting migraine…
The amyloid hypothesis of Alzheimer's has taken another battering – and some companies are finally taking a new approach.
Biohaven might soon be going up against Allergan in the acute migraine space, but the company believes size will not be a barrier to its success.